Tarsus Pharmaceuticals Appoints Former Allergan CEO David Pyott to Board, Chairing Commercial Committee

summarizeSummary

Tarsus Pharmaceuticals appointed David E.I. Pyott, former Chairman and CEO of Allergan, Inc., to its Board of Directors, where he will also chair the Commercial Committee, bringing significant biopharmaceutical and eye care leadership experience.

check_boxKey Events

• New Director Appointment

  David E.I. Pyott, former Chairman and CEO of Allergan, Inc., has been appointed to the Board of Directors, expanding the board from seven to eight members.

• Key Committee Leadership

  Mr. Pyott will serve as Chairperson of the Commercial Committee and as a member of both the Nominating and Compensation Committees.

• Renowned Industry Expertise

  Mr. Pyott brings decades of global leadership, having transformed Allergan into a multi-billion dollar specialty pharmaceutical and medical device leader, with a strong track record in eye care.

• Director Compensation

  As a non-employee director, Mr. Pyott will receive cash and equity compensation, including an initial grant with a target value of $540,000 (50% options, 50% RSUs).

auto_awesomeAnalysis

Tarsus Pharmaceuticals has significantly strengthened its Board of Directors with the appointment of David E.I. Pyott, the highly respected former Chairman and CEO of Allergan, Inc. Mr. Pyott's extensive experience in scaling biopharmaceutical businesses, particularly in eye care, is directly relevant to Tarsus's strategic objectives, including the commercialization of XDEMVY and advancing its pipeline. His immediate appointment as Chairperson of the Commercial Committee underscores the company's focus on leveraging his expertise for market growth. This move signals a strong commitment to enhancing commercial strategy and operational excellence.